Description
Iverjohn (Ivermectin) 6 mg
Iverjohn 6 mg is an ivermectin tablet product. Ivermectin is an antiparasitic medicine used in human medicine for certain nematode infections. The verified clinical uses and safety profile below are based on official prescribing information for ivermectin tablets and peer-reviewed medical literature.
Active Ingredient and Medicine Class
The active ingredient is ivermectin, a macrocyclic lactone anthelmintic and antiparasitic agent. It acts selectively against invertebrate parasites and is widely used in human parasitic disease treatment.
Established Medical Uses
Official U.S. prescribing information for ivermectin tablets lists treatment of intestinal strongyloidiasis due to Strongyloides stercoralis and onchocerciasis due to Onchocerca volvulus. The label also notes that ivermectin has no activity against adult Onchocerca volvulus parasites.
How It Works
Ivermectin works by binding to and activating parasite glutamate-gated chloride channels, which increases chloride ion flow, disrupts nerve and muscle function in the parasite, and leads to paralysis and death. Human cells do not have these parasite-specific channels.
Important Safety Information
Ivermectin tablets are contraindicated in people with hypersensitivity to any component of the product. The label warns that treatment of onchocerciasis may trigger inflammatory reactions related to dying microfilariae, including cutaneous, eye-related, and systemic reactions. Serious neurotoxicity has been reported, including altered consciousness, confusion, disorientation, coma, and death. Patients with heavy Loa loa infection may be at risk of severe or fatal encephalopathy.
Possible Side Effects
Reported adverse effects include itching, rash, swelling, dizziness, diarrhea, nausea, abdominal discomfort, and other reactions related to parasite death in onchocerciasis. Rare but serious reactions include severe skin reactions, hepatitis, and neurological toxicity.
Scientific Evidence
Clinical studies and reviews support ivermectin’s established role in strongyloidiasis and onchocerciasis, with substantial cure or marked parasite reduction in treated patients. Reviews also describe generally low rates of adverse reactions in standard antiparasitic use, while emphasizing important risks in specific infections such as loiasis-associated disease.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet or assessment by a qualified healthcare professional.
Medical Sources
- DailyMed / U.S. Prescribing Information: Ivermectin Tablets, USP
- FDA Prescribing Information: STROMECTOL (ivermectin) Tablets
- P. González et al.: Ivermectin in human medicine, an overview of the current status of its clinical applications. Curr Pharm Biotechnol. 2012.
